Ireland
--:--IST
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Washington
Clinical trial register · United States · industry-sponsored

Clinical Trials in Washington, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 232 Florida 174 Arizona 114 Illinois 110 Georgia 105
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Washington

11 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
27
Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington
2026-01-09
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 1
304
California, Kansas, Maryland, Michigan, New York, Texas, Virginia, Washington
2021-03-09
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
AstraZeneca
Phase 3
140
Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington
2019-10-29
Active, closed
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03778229Carcinoma
AstraZeneca
Phase 2
367
California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2019-01-09
Active, closed
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
NCT03459846Urinary Bladder Neoplasms
AstraZeneca
Phase 2
154
Alabama, Arizona, Florida, Kentucky, New York, Pennsylvania, Tennessee, Washington
2018-03-16
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/washington

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Washington that also match the filters currently applied.

How many clinical trials are recruiting in Washington?

5 of the 11 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Washington), 11 studies
PhaseStudiesRecruitingShare
Phase 14336.4%
Phase 34136.4%
Phase 22018.2%
Phase 1/2119.1%

Most active sponsors

Lead sponsors with the most studies (Washington)
Lead sponsorStudiesRecruiting
AstraZeneca115
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.